Avalo Therapeutics, Inc. (AVTX)
19.23
+0.23
(+1.21%)
USD |
NASDAQ |
Sep 04, 16:00
19.24
+0.01
(+0.05%)
After-Hours: 20:00
Avalo Therapeutics Research and Development Expense (Quarterly) : 23.42M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 23.42M |
| March 31, 2026 | 14.05M |
| December 31, 2025 | 13.27M |
| September 30, 2025 | 13.62M |
| June 30, 2025 | 14.07M |
| March 31, 2025 | 9.123M |
| December 31, 2024 | 8.183M |
| September 30, 2024 | 9.538M |
| June 30, 2024 | 4.601M |
| March 31, 2024 | 2.116M |
| December 31, 2023 | 1.867M |
| September 30, 2023 | 1.249M |
| June 30, 2023 | 4.658M |
| March 31, 2023 | 6.008M |
| December 31, 2022 | 6.172M |
| September 30, 2022 | 7.042M |
| June 30, 2022 | 8.51M |
| March 31, 2022 | 9.584M |
| December 31, 2021 | 11.51M |
| September 30, 2021 | 10.55M |
| June 30, 2021 | 12.57M |
| March 31, 2021 | 25.21M |
| December 31, 2020 | 12.64M |
| September 30, 2020 | 8.872M |
| Date | Value |
|---|---|
| June 30, 2020 | 5.917M |
| March 31, 2020 | 4.768M |
| September 30, 2019 | 1.743M |
| June 30, 2019 | 3.713M |
| March 31, 2019 | 3.401M |
| December 31, 2018 | 2.006M |
| September 30, 2018 | 1.048M |
| June 30, 2018 | 1.083M |
| March 31, 2018 | 1.650M |
| December 31, 2017 | 1.961M |
| September 30, 2017 | 0.9646M |
| June 30, 2017 | 0.4936M |
| March 31, 2017 | 0.9531M |
| December 31, 2016 | 0.773M |
| September 30, 2016 | 4.582M |
| June 30, 2016 | 2.502M |
| March 31, 2016 | 2.293M |
| December 31, 2015 | 1.751M |
| September 30, 2015 | 1.237M |
| June 30, 2015 | 1.875M |
| March 31, 2015 | 1.723M |
| June 30, 2014 | 2.861M |
| March 31, 2014 | 2.750M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Incyte Corp. | 497.47M |
| AbbVie, Inc. | 2.344B |
| Rezolute, Inc. | 11.41M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |